恩考芬尼联合比美替尼治疗BRAF V600E突变转移性非小细胞肺癌的2期PHAROS研究更新疗效与安全性:简报
PHAROS研究在BRAF V600E突变转移性NSCLC患者中评估恩考芬尼450 mg每日一次联合比美替尼45 mg每日两次。中位随访延长后,初治患者客观缓解率75%、中位无进展生存期30.2个月、3年总生存概率53%;经治患者分别为46%、9.3个月、29%,安全性总体可控。
要点
- 初治患者客观缓解率75%,中位缓解持续时间40.0个月,中位无进展生存期30.2个月。
- 经治患者客观缓解率46%,中位缓解持续时间16.7个月,中位无进展生存期9.3个月。
- 治疗相关不良事件致剂量降低25例(26%)、永久停药16例(16%)。
核心结论
- 延长随访后,恩考芬尼联合比美替尼在BRAF V600E突变转移性NSCLC中显示出持久且有临床意义的抗肿瘤活性,尤其在初治患者中,安全性可控。
研究设计与样本
- 正在进行中的开放标签、单臂、2期研究,纳入BRAF V600E突变转移性NSCLC患者59例初治和39例经治。
- 给药方案为恩考芬尼450 mg每日一次联合比美替尼45 mg每日两次,主要终点为客观缓解率。
主要发现
- 初治患者中位治疗持续时间16.3个月,最短随访约32个月;经治患者分别为5.5个月和约22个月。
- 初治患者客观缓解率75%,中位缓解持续时间40.0个月,中位无进展生存期30.2个月,中位总生存期不可估计(95%CI:31.3-不可估计),3年总生存概率53%。
- 经治患者客观缓解率46%,中位缓解持续时间16.7个月,中位无进展生存期9.3个月,中位总生存期22.7个月,3年总生存概率29%。
- 最常见的治疗相关不良事件为恶心(52%)、腹泻(44%)、乏力(33%)和呕吐(30%)。
- 治疗相关不良事件导致剂量降低25例(26%)、永久停药16例(16%)。
关键数值与推荐
- 初治患者:客观缓解率75%,中位缓解持续时间40.0个月,中位无进展生存期30.2个月,中位总生存期不可估计(95%CI:31.3-不可估计),3年总生存概率53%。
- 经治患者:客观缓解率46%,中位缓解持续时间16.7个月,中位无进展生存期9.3个月,中位总生存期22.7个月,3年总生存概率29%。
- 治疗相关不良事件致剂量降低25例(26%)、永久停药16例(16%)。
临床怎么用
- 作者认为,在BRAF V600E突变转移性NSCLC患者中,恩考芬尼联合比美替尼显示出持久且有临床意义的抗肿瘤活性,尤其在初治患者中,安全性可控。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The PHAROS primary analysis revealed robust antitumor activity and acceptable safety with encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). We report results after 18 months of additional follow-up. METHODS: In this ongoing open-label, single-arm, phase 2 study, patients with BRAF V600E-mutant mNSCLC (59 treatment-naive and 39 previously treated) received encorafenib 450 mg once daily and binimetinib 45 mg twice daily. Primary end point was objective response rate (ORR). Secondary end points included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: At this data cutoff, median treatment duration with encorafenib plus binimetinib was 16.3 months in treatment-naive and 5.5 months in previously treated patients; minimum follow-up was approximately 32 and 22 months, respectively. In treatment-naive patients, the ORR was 75%, median DOR was 40.0 months, median PFS was 30.2 months, median OS was not estimable (95% confidence interval: 31.3-not estimable), and the 3-year OS probability was 53%. In previously treated patients, the ORR was 46%, median DOR was 16.7 months, median PFS was 9.3 months, median OS was 22.7 months, and the 3-year OS probability was 29%. Overall, the most frequent treatment-related adverse events were nausea (52%), diarrhea (44%), fatigue (33%), and vomiting (30%). Treatment-related adverse events led to dose reductions and permanent treatment discontinuations in 25 (26%) and 16 (16%) patients, respectively. CONCLUSIONS: With longer follow-up, encorafenib plus binimetinib showed durable and clinically meaningful antitumor activity, especially in treatment-naive patients, with a manageable safety profile in patients with BRAF V600E-mutant mNSCLC. CLINICAL TRIAL INFORMATION: ClinicalTrials.gov Identifier: NCT03915951.
引用
- Riely GJ, Ahn MJ, Clarke JM, et al. Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report. J Thorac Oncol. 2025. PMID: 40480428. doi:10.1016/j.jtho.2025.05.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。